Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer

Early Phase 1

Completed

Conditions: Cognitive Side Effects of Cancer Therapy
Recurrent Breast Carcinoma
Stage IA Breast Cancer
Stage IB Breast Cancer
Depression
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer

Brief Summary: This randomized clinical trial uses an inactive typhoid vaccine to briefly stimulate an immune response in patients with stage I-IIIA breast cancer who received primary cancer treatment and studies whether patients' fitness levels affect how their bodies handle a challenge to their immune system. A vaccine is a substance or group of substances meant to cause the immune system to respond to a tumor or to microorganisms such as bacteria or viruses. Immune responses may cause excess inflammation in the body and behavioral changes, such as depression, fatigue, pain, and problems with thinking and reasoning. Studying immune responses in patients with breast cancer who have undergone primary cancer treatment may help doctors learn whether physical fitness can protect the body from effects of immune system stress and whether it may be able to reduce health problems in patients with breast cancer.

Detailed Description: PRIMARY OBJECTIVES:

I. To evaluate the relationships between cardiorespiratory fitness and inflammatory and behavioral responses (negative mood, fatigue, pain, and cognitive problems) to typhoid vaccine in breast cancer survivors.

II. To determine the effects of age and depressive symptoms on inflammatory and behavioral responses to typhoid vaccine and placebo.

III. To assess the ability of cardiorespiratory fitness to moderate age- and depression-related responses to typhoid vaccine.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive inactive typhoid vaccine intramuscularly (IM) at visit 1 followed by placebo IM 30 days later at visit 2.

ARM II: Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.

There is an initial screening visit where patients in both arms complete an audio-recorded interview that includes questions about changes in mood and emotion throughout their lives, body measurements, a finger stick to assess for anemia and diabetes markers. During visit 1 and 2, patients in both arms will have blood drawn periodically and complete sets of questionnaires that assess feelings, health behaviors, and personality. Patients also complete cognitive tasks and a temperature sensitivity task at 3-4.5 hours post-injection.

Recruitment & Eligibility

Inclusion Criteria

Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-10 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors)
All women will be postmenopausal

Exclusion Criteria

A prior history of any other malignancy except basal or squamous cell skin cancers, strokes, diabetes, current heart disease or uncontrolled hypertension, peripheral vascular disease, liver disease, autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis, and other medical conditions that would limit participation in the assessments (e.g., pulmonary disease, orthopedic problems, major psychiatric illness, major cognitive dysfunction, or an acute medical problem)
Anemia
Alcohol or drug abuse
Smoking
Medication exclusions will include steroids as well as statins and other medications with anti-inflammatory actions
Women who have received a typhoid vaccine within the last three years

Arm && Interventions

Group	Intervention	Description
Arm II (placebo, inactive typhoid vaccine)	Placebo	Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
Arm II (placebo, inactive typhoid vaccine)	typhoid vaccine	Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
Arm I (inactive typhoid vaccine, placebo)	typhoid vaccine	Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
Arm I (inactive typhoid vaccine, placebo)	Placebo	Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.

Primary Outcome Measures

Name	Time	Method
AUC Change in Level of IL-6	Baseline, 1.5, 3, 5, 6.5, 8 hours post vaccine	AUC change refers to the 'net incremental' area, which is the area under the curve above the baseline value. Data points used in AUC change calculation include baseline, 1.5, 3, 5, 6.5, 8 hours post vaccine. This can be calculated geometrically by applying the trapezoid rule. When a value falls below the baseline, only the area above the baseline level is included.

Secondary Outcome Measures

Name	Time	Method
AUC Change in Fatigue	baseline, 2, 3.5, 5, 6.5, 8.5 hours post vaccine	Self-reported intensity of fatigue on 0-9 scales (0 = no fatigue; 9 = fatigue as bad as you can imagine). AUC change refers to the 'net incremental' area, which is the area under the curve above the baseline value. Data points used in AUC change calculation include baseline, 2, 3.5, 5, 6.5, 8.5 hours post vaccine. This can be calculated geometrically by applying the trapezoid rule. When a value falls below the baseline, only the area above the baseline level is included.
AUC Change in Pain	baseline, 2, 3.5, 5, 6.5, 8.5 hours post vaccine	Self-reported intensity of pain on 0-9 scale (0 = no pain; 9 = pain as bad as you can imagine). AUC change refers to the 'net incremental' area, which is the area under the curve above the baseline value. Data points used in AUC change calculation include baseline, 2, 3.5, 5, 6.5, 8.5 hours post vaccine. This can be calculated geometrically by applying the trapezoid rule. When a value falls below the baseline, only the area above the baseline level is included.

Locations (1): Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Wexner Medical Center
🇺🇸
Columbus, Ohio, United States